Management and outcomes of cardiac sarcoidosis

a 20-year experience in two tertiary care centres

Lynn A. Fussner, Erin Karlstedt, David O. Hodge, Nowell M. Fine, Sanjay Kalra, Eva M Carmona Porquera, James P Utz, Debra L. Isaac, Leslie T Jr. Cooper

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Aims: Cardiac sarcoidosis (CS) often presents with ventricular arrhythmias, heart block, and cardiomyopathy. The prognosis of CS with contemporary management is uncertain. We estimated the impact of baseline and treatment variables on left ventricular ejection fraction (LVEF), ventricular assist device placement, heart transplant, and death. Methods and results: We identified patients with CS seen from 1994–2014 at two large academic medical centres. All met the 2014 Heart Rhythm Society expert consensus criteria for diagnosis. From the 574 patients identified, 91 met inclusion criteria. Twenty-two (24.2%) were diagnosed by endomyocardial biopsy. Cardiomyopathy was the primary presentation in 47 patients (51.6%). Within 90 days of diagnosis, 41 patients (45.0%) received prednisone alone, 29 (31.9%) received alternative immunosuppression with or without prednisone, and 21 (23.1%) received no immunosuppression. During follow-up, 31 of 47 cardiomyopathy patients experienced improvement in LVEF, while 23 experienced decline in LVEF or clinical exacerbation, and 15 of 22 patients presenting with ventricular arrhythmia had recurrence. These results did not differ by treatment group. During a median follow-up of 44 months for our cohort, 14 patients reached the composite endpoint of ventricular assist device placement, heart transplant, or death. Survival without the composite outcome did not differ by treatment group, but was worse among patients presenting with cardiomyopathy (log-rank = 0.005). Conclusion: In a large series of CS subjects, rates of ventricular arrhythmia and heart failure events remain high with no treatment regimen clearly associated with better outcome. Patients with cardiomyopathy at diagnosis were more likely to reach the composite endpoint.

Original languageEnglish (US)
JournalEuropean Journal of Heart Failure
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Sarcoidosis
Tertiary Care Centers
Cardiomyopathies
Stroke Volume
Cardiac Arrhythmias
Heart-Assist Devices
Prednisone
Immunosuppression
Transplants
Heart Block
Therapeutics
Heart Failure
Biopsy
Recurrence
Survival

Keywords

  • Cardiac sarcoidosis
  • Cardiomyopathy
  • Sarcoidosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Management and outcomes of cardiac sarcoidosis : a 20-year experience in two tertiary care centres. / Fussner, Lynn A.; Karlstedt, Erin; Hodge, David O.; Fine, Nowell M.; Kalra, Sanjay; Carmona Porquera, Eva M; Utz, James P; Isaac, Debra L.; Cooper, Leslie T Jr.

In: European Journal of Heart Failure, 01.01.2018.

Research output: Contribution to journalArticle

@article{a40f0e77369a44bdab6b542bc7fd8cdb,
title = "Management and outcomes of cardiac sarcoidosis: a 20-year experience in two tertiary care centres",
abstract = "Aims: Cardiac sarcoidosis (CS) often presents with ventricular arrhythmias, heart block, and cardiomyopathy. The prognosis of CS with contemporary management is uncertain. We estimated the impact of baseline and treatment variables on left ventricular ejection fraction (LVEF), ventricular assist device placement, heart transplant, and death. Methods and results: We identified patients with CS seen from 1994–2014 at two large academic medical centres. All met the 2014 Heart Rhythm Society expert consensus criteria for diagnosis. From the 574 patients identified, 91 met inclusion criteria. Twenty-two (24.2{\%}) were diagnosed by endomyocardial biopsy. Cardiomyopathy was the primary presentation in 47 patients (51.6{\%}). Within 90 days of diagnosis, 41 patients (45.0{\%}) received prednisone alone, 29 (31.9{\%}) received alternative immunosuppression with or without prednisone, and 21 (23.1{\%}) received no immunosuppression. During follow-up, 31 of 47 cardiomyopathy patients experienced improvement in LVEF, while 23 experienced decline in LVEF or clinical exacerbation, and 15 of 22 patients presenting with ventricular arrhythmia had recurrence. These results did not differ by treatment group. During a median follow-up of 44 months for our cohort, 14 patients reached the composite endpoint of ventricular assist device placement, heart transplant, or death. Survival without the composite outcome did not differ by treatment group, but was worse among patients presenting with cardiomyopathy (log-rank = 0.005). Conclusion: In a large series of CS subjects, rates of ventricular arrhythmia and heart failure events remain high with no treatment regimen clearly associated with better outcome. Patients with cardiomyopathy at diagnosis were more likely to reach the composite endpoint.",
keywords = "Cardiac sarcoidosis, Cardiomyopathy, Sarcoidosis",
author = "Fussner, {Lynn A.} and Erin Karlstedt and Hodge, {David O.} and Fine, {Nowell M.} and Sanjay Kalra and {Carmona Porquera}, {Eva M} and Utz, {James P} and Isaac, {Debra L.} and Cooper, {Leslie T Jr.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/ejhf.1319",
language = "English (US)",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Oxford University Press",

}

TY - JOUR

T1 - Management and outcomes of cardiac sarcoidosis

T2 - a 20-year experience in two tertiary care centres

AU - Fussner, Lynn A.

AU - Karlstedt, Erin

AU - Hodge, David O.

AU - Fine, Nowell M.

AU - Kalra, Sanjay

AU - Carmona Porquera, Eva M

AU - Utz, James P

AU - Isaac, Debra L.

AU - Cooper, Leslie T Jr.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Aims: Cardiac sarcoidosis (CS) often presents with ventricular arrhythmias, heart block, and cardiomyopathy. The prognosis of CS with contemporary management is uncertain. We estimated the impact of baseline and treatment variables on left ventricular ejection fraction (LVEF), ventricular assist device placement, heart transplant, and death. Methods and results: We identified patients with CS seen from 1994–2014 at two large academic medical centres. All met the 2014 Heart Rhythm Society expert consensus criteria for diagnosis. From the 574 patients identified, 91 met inclusion criteria. Twenty-two (24.2%) were diagnosed by endomyocardial biopsy. Cardiomyopathy was the primary presentation in 47 patients (51.6%). Within 90 days of diagnosis, 41 patients (45.0%) received prednisone alone, 29 (31.9%) received alternative immunosuppression with or without prednisone, and 21 (23.1%) received no immunosuppression. During follow-up, 31 of 47 cardiomyopathy patients experienced improvement in LVEF, while 23 experienced decline in LVEF or clinical exacerbation, and 15 of 22 patients presenting with ventricular arrhythmia had recurrence. These results did not differ by treatment group. During a median follow-up of 44 months for our cohort, 14 patients reached the composite endpoint of ventricular assist device placement, heart transplant, or death. Survival without the composite outcome did not differ by treatment group, but was worse among patients presenting with cardiomyopathy (log-rank = 0.005). Conclusion: In a large series of CS subjects, rates of ventricular arrhythmia and heart failure events remain high with no treatment regimen clearly associated with better outcome. Patients with cardiomyopathy at diagnosis were more likely to reach the composite endpoint.

AB - Aims: Cardiac sarcoidosis (CS) often presents with ventricular arrhythmias, heart block, and cardiomyopathy. The prognosis of CS with contemporary management is uncertain. We estimated the impact of baseline and treatment variables on left ventricular ejection fraction (LVEF), ventricular assist device placement, heart transplant, and death. Methods and results: We identified patients with CS seen from 1994–2014 at two large academic medical centres. All met the 2014 Heart Rhythm Society expert consensus criteria for diagnosis. From the 574 patients identified, 91 met inclusion criteria. Twenty-two (24.2%) were diagnosed by endomyocardial biopsy. Cardiomyopathy was the primary presentation in 47 patients (51.6%). Within 90 days of diagnosis, 41 patients (45.0%) received prednisone alone, 29 (31.9%) received alternative immunosuppression with or without prednisone, and 21 (23.1%) received no immunosuppression. During follow-up, 31 of 47 cardiomyopathy patients experienced improvement in LVEF, while 23 experienced decline in LVEF or clinical exacerbation, and 15 of 22 patients presenting with ventricular arrhythmia had recurrence. These results did not differ by treatment group. During a median follow-up of 44 months for our cohort, 14 patients reached the composite endpoint of ventricular assist device placement, heart transplant, or death. Survival without the composite outcome did not differ by treatment group, but was worse among patients presenting with cardiomyopathy (log-rank = 0.005). Conclusion: In a large series of CS subjects, rates of ventricular arrhythmia and heart failure events remain high with no treatment regimen clearly associated with better outcome. Patients with cardiomyopathy at diagnosis were more likely to reach the composite endpoint.

KW - Cardiac sarcoidosis

KW - Cardiomyopathy

KW - Sarcoidosis

UR - http://www.scopus.com/inward/record.url?scp=85055894695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055894695&partnerID=8YFLogxK

U2 - 10.1002/ejhf.1319

DO - 10.1002/ejhf.1319

M3 - Article

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

ER -